Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians

Gut

Volumn 64, Issue 8, 2015, Pages 1289-1295

  Arends, Pauline ^a   Sonneveld, Milan J ^a   Zoutendijk, Roeland ^a   Carey, Ivana ^b   Brown, Ashley ^c   Fasano, Massimo ^d   Mutimer, David ^e   Deterding, Katja ^f   Reijnders, Jurriën G P ^a   Oo, Ye ^e   Petersen, Jörg ^g   Van Bömmel, Florian ^h   De Knegt, Robert J ^a   Santantonio, Teresa ^d   Berg, Thomas ^h   Welzel, Tania M ⁱ   Wedemeyer, Heiner ^f   Buti, Maria ^j   Pradat, Pierre ^k   Zoulim, Fabien ^k   Hansen, Bettina ^a   Janssen, Harry L A ^a,l   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF FOGGIA   (Italy)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k CROIX ROUSSE HOSPITAL   (France)

^l TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; AGE; ARTICLE; CAUCASIAN; CHRONIC HEPATITIS B; COHORT ANALYSIS; CU HCC SCORE; DRUG RESPONSE; EUROPE; FEMALE; FOLLOW UP; GAG HCC SCORE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; REACH B SCORE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84938231238     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307023     Document Type: Article

References (13)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-500.
2. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-85.
3. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-2.
4. Chen CJ, Yang HI, Su J, et al Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
5. Chang TT, Liaw YF, Wu S.S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886-93.
6. Zoutendijk R, Reijnders JG, Zoulim F, et al Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2012; 62:760-5.
7. Hosaka T, Suzuki F, Kobayashi M., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58:98-107.
8. Wong GL, Chan HL, Mak C.H., et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58:1537-47.
9. Wong GL, Chan HL, Chan H.Y., et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013; 144:933-44.
10. Wong VW, Chan SL, Mo F, et al Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28:1660-5.
11. Yuen MF, Tanaka Y, Fong D.Y., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50:80-8.
12. Yang HI, Yuen MF, Chan H.L., et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12:568-74.
13. Papatheodoridis GV, Manolakopoulos S, Touloumi G., et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60:1109-16.